REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

NCT00287287 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Neoplasms

Interventions

DRUG: Lenalidomide

Sponsor

Kenneth Ain

Collaborators

[object Object]